Respiratory syncytial virus Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
GlaxoSmithKline750 enrolled13 locationsNCT07220109
Recruiting
Phase 3
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
Respiratory Syncytial Virus Infections
Kexing Biopharm Co., Ltd.322 enrolled1 locationNCT06363370